恩替卡韦治疗慢性乙型肝炎的临床疗效观察及安全性评价

Clinical Efficacy and Safety Evaluation of Entecavir in the Treatment of Chronic Hepatitis B

目的:探讨恩替卡韦治疗慢性乙型肝炎的临床疗效及安全性。方法:选取2016年9月—2017年8月期间在我院治疗的92例慢性乙型肝炎患者,利用随机数字表法分为两组,各46例。对照组采用拉米夫定治疗,观察组采用恩替卡韦治疗,对比两组临床疗效、肝功能、HBV-DNA及不良反应发生情况。结果:对照组治疗总有效率较观察组低,差异有统计学意义(P<0.05);治疗后,两组TBiL、ALT、AST及HBV-DNA水平均降低,且观察组较对照组低,差异有统计学意义(P<0.05);两组不良反应发生率对比,差异无统计学意义(P>0.05)。结论:慢性乙型肝炎患者采取恩替卡韦进行治疗可有效提升临床疗效,有效抑制HBV复制,改善患者肝功能,且安全性较高。

Objective:To evaluate the efficacy and safety of entecavir in the treatment of chronic hepatitis B.Methods:92 patients with chronic hepatitis B who were treated in our hospital from September 2016 to August 2017 were randomly divided into two groups,46 cases in each group.The control group was treated with lamivudine and the observation group was treated with entecavir.The clinical efficacy,liver function,HBV-DNA and adverse reactions were compared between the two groups.Results:The total effective rate in the control group was significantly lower than that in the observation group(P<0.05).After treatment,the TBiL,ALT,AST and HB in the two groups were lower than those in the observation group.The level of V-DNA in the observation group was lower than that in the control group(P<0.05),and there was no significant difference in the incidence of adverse reactions between the two groups(P>0.05).Conclusion:Enticavir therapy in patients with chronic hepatitis B can effectively improve the clinical efficacy,inhibit HBV replication and improve liver function.